Limitless Potential.
Precision Design.
Enduring Impact.

Aiming to transform treatment of cancer and autoimmune and inflammatory diseases by developing allogeneic, iPSC-derived NK and T cell therapies.
PRESS RELEASES + EVENTS view all
14-March-2024
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
– Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas…
05-March-2024
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing,…

About us

We are building an industry leading allogeneic iPSC-derived cell therapy platform for cancer and autoimmune and inflammatory diseases.

OUR SCIENCE

We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.

Contact us

For business development, media, and all other inquiries.